UC San Diego

1. Merck Sharp & Dohme Corporation $8,349,219 22 payments
2. GenMark Diagnostics, Inc. $1,261,751 78 payments
3. Swedish Orphan Biovitrum AB $100,000 1 payment
4. Dexcom, Inc. $52,025 3 payments
5. Astellas Pharma Global Development $19,370 1 payment
6. Amgen Inc. $12,965 1 payment
7. GT Medical Technologies, Inc $11,622 1 payment
8. Organon LLC $665 1 payment

1. Phase II Randomized Trial of Radiotherapy Alone Versus Radiotherapy with Concurrent and Adjuvant Pembrolizumab in Patients with p16 Stage III-IVA Head and Neck Squamous Cell Carcinoma $3,940,770 4 payments
2. An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma ccRCC $1,544,280 9 payments
3. An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First $797,490 1 payment
4. Ctp0030 $731,561 34 payments
5. An open-label, non-randomized, multi-arm, phase II trial to evaluate the efficacy of pembrolizumab combined with cetuximab in patients with recurrent, metastatic head and neck squamous cell carcinoma HNSCC $717,202 2 payments
6. STUDY NAME#Phase II Randomized Trial of Radiotherapy with Concurrent Cisplatin Versus Radiotherapy with Concurrent and Adjuvant Pembrolizumab in Patients with Intermediate,High-Risk p16 Head and Neck Squamous Cell Carcinoma $619,443 1 payment
7. STUDY NAME#Phase II Randomized Trial of Radiotherapy with Concurrent Cisplatin Versus Radiotherapy with Concurrent and Adjuvant Pembrolizumab in Patients with Intermediate,High-Risk p16 Head and Neck Squamous Cell Carcinoma $353,910 1 payment
8. An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab MK-3475 in Combination with Belzutifan MK-6482 and Lenvatinib MK-7902, or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First $317,789 1 payment
9. Ctp0011 $233,087 34 payments
10. Ctp0023 $115,929 7 payments

1. Other $11,622 1 payment
2. Patient care $665 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.